Trial Profile
Efficacy of Denosumab in subjects from a Japanese registry (TBCR-BONE) suffering from osteoporosis and rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TBCR-BONE
- 06 Jun 2020 Results (n=46) of retrospective analysis to assess efficacy of 5 year treatment using data from TBCR-BONE presented at the 21st Annual Congress of the European League Against Rheumatism
- 15 Jun 2019 Results evaluating the treatment goal of Denosumab in patients with osteoporosis, who completed 3-year DMB treatment, are presented at the 20th Annual Congress of the European League Against Rheumatism
- 10 Feb 2016 New trial record